RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Genetic Technologies - Stock

Genetic Technologies Market capitalization 2024

Genetic Technologies Market capitalization

9.83 M AUD

Ticker

GTG.AX

ISIN

AU000000GTG7

WKN

893882

In 2024, Genetic Technologies's market cap stood at 9.83 M AUD, a 4,166.19% increase from the 230,508.7 AUD market cap in the previous year.

The Genetic Technologies Market capitalization history

YEARREVENUE (undefined AUD)GROSS MARGIN (%)NET INCOME (undefined AUD)
20238.6950,09-11,750.92
20226.7955,65-7,131
20210.12-41,40-7,077.62
20200.01-928,70-6,294.78
20190.03-985,97-6,425.6
20180.19-58,57-5,463.87
20170.525,03-8,403.83
20160.829,89-8,458.97
20152.0155,70-8,810.17
20144.5659,87-10,130
20133.3842,31-9,300
20123.6947,15-5,290
20114.5955,77910
20109.9772,72-9,340
200912.1875,78-7,840
200815.9889,99-5,450
200715.3287,01-4,330
200610.7681,32-7,920
200510.8584,42-10,470
20045.4252,03-10,710

Genetic Technologies Aktienanalyse

What does Genetic Technologies do?

Genetic Technologies Ltd is an Australian biotechnology company that was founded in 1989. The company is an internationally recognized provider of genomic analysis procedures and technologies and has been operating in various business sectors since its establishment. Genetic Technologies is headquartered in Melbourne, Australia, and maintains offices in the USA, Europe, and Asia. The company's business model is based on the development and commercialization of genetic analysis systems and technologies. Genetic Technologies serves a wide range of customers, including research institutes, universities, diagnostic laboratories, biotechnology companies, and pharmaceutical companies. The company specializes in the analysis of DNA sequences and offers various genetic testing procedures to, for example, identify genetic risk factors for certain diseases or determine the ancestry of individuals. Genetic Technologies' different business sectors include clinical diagnostics, agriculture, forensic science, and scientific research. The company develops and markets various genetic testing procedures, such as the BREVAGenplus test, which aims to help women determine their risk for breast and ovarian cancer. Genetic Technologies also plays a leading role in agriculture, offering, for example, the CalfStart test, which allows breeders to determine the genetic potential of their calves. In forensic science, Genetic Technologies develops DNA tests that help solve criminal cases and identify perpetrators. Furthermore, the company also provides genetic counseling services. Another important area of Genetic Technologies is the development and commercialization of genetic analysis procedures and technologies. The company holds several patents worldwide for DNA analysis procedures, including the patented non-coding procedure, which represented a significant breakthrough in genomic research. Genetic Technologies' chairman, Dr. Mervyn Jacobson, is a recognized expert in the field of genomic research and has already authored numerous scientific publications on this topic. In addition to its various business sectors and products, Genetic Technologies has also established close relationships with other companies and institutions in the biotechnology industry. For example, the company collaborates closely with the USA-based HudsonAlpha Institute for Biotechnology to jointly develop innovative DNA technologies and procedures. Overall, Genetic Technologies has made a name for itself as a company specializing in the analysis of DNA sequences. Through its innovative products and services, the company has contributed to advancing genomic research and gaining new insights into the genetic basis of diseases and other phenomena. With its broad range of business sectors and international presence, Genetic Technologies is an important player in the biotechnology industry and is likely to further expand in the coming years. Genetic Technologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Genetic Technologies's Market Capitalization

Genetic Technologies's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Genetic Technologies's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Genetic Technologies's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Genetic Technologies’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Genetic Technologies Stock

What is the current Genetic Technologies market capitalization?

The current market capitalization of Genetic Technologies is 9.83 M AUD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Genetic Technologies.

How has the market capitalization of Genetic Technologies developed in recent years?

The market capitalization of Genetic Technologies has increased/decreased by 4,166.19% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Genetic Technologies?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Genetic Technologies?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Genetic Technologies have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Genetic Technologies pay?

Over the past 12 months, Genetic Technologies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Genetic Technologies is expected to pay a dividend of 0 AUD.

What is the dividend yield of Genetic Technologies?

The current dividend yield of Genetic Technologies is .

When does Genetic Technologies pay dividends?

Genetic Technologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Genetic Technologies?

Genetic Technologies paid dividends every year for the past 0 years.

What is the dividend of Genetic Technologies?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Genetic Technologies located?

Genetic Technologies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Genetic Technologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Genetic Technologies from 6/11/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 6/11/2024.

When did Genetic Technologies pay the last dividend?

The last dividend was paid out on 6/11/2024.

What was the dividend of Genetic Technologies in the year 2023?

In the year 2023, Genetic Technologies distributed 0 AUD as dividends.

In which currency does Genetic Technologies pay out the dividend?

The dividends of Genetic Technologies are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Genetic Technologies

Our stock analysis for Genetic Technologies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genetic Technologies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.